About Us: Dr. Arthur P. Chou, M.D. Ph.D.
- Take care of my patients in the best ways possible
- Provide compassionate care
- Obtain the best possible results for my patients
- Neurosurgery Residency: UCLA Medical Center
- Medical School: David Geffen School of Medicine at UCLA
Languages spoken: English and mandarin Chinese
- California Medical License: A111306
- Board Eligible for the American Board of Neurological Surgery
Honors and Awards:
- 2012: American Brain Tumor Association Basic Research Fellowship
- 2012: American Association of Neurological Surgeons Springer Journal of Neuro-Oncology Award
- 2011: UCLA Department of Neurosurgery Harold and Mimi Steinberg Resident Award for Academic Excellence
- 2011: Congress of Neurological Surgeons Wilder Penfield Fellowship
- 2011: American Association of Neurological Surgeons Neurosurgery Research and Education Foundation Fellowship
- 2011: American Association of Neurological Surgeons Stryker Neuro-Oncology Award
Research interest and publications:
- My research interest is in a type of malignant brain tumors called gliomas. I worked with researchers at UCLA to better understand gliomas and how better to treat them. Some of my publications include:
- Chou AP, Chowdhury R, Li S et al. Identification of Retinol Binding Protein 1 (RBP1) Promoter Hypermethylation in IDH1/IDH2 Mutant Gliomas. J. Natl. Cancer Institute, 104(19):1458-69, 2012. doi: 10.1093/jnci/djs357.
- Li S, Chou AP, Chen W et al. Overexpression of isocitrate dehydrogenase 1 (IDH1) R132H mutant protein renders U87 glioma cells less malignant and more sensitive to radiation. Neuro-Oncology, 15(1):57-68, 2013. doi: 10.1093/neuonc/nos261.
- Lalezari S, Chou AP, Tran A et al. Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation. Neuro-Oncology, 15(3):370-81, March 2013.doi: 10.1093/neuonc/nos308.
- Piccioni DE, Selfridge J, Mody RR et al. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncology, 2014, Jun, 16(6). doi: 10.1093/neuonc/nou028.
- Li S, Chowdhury R, Liu F et al. Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas. Clin Cancer Res. 2014, Sept 2014. doi: 10.1158/1078-0432.CCR-14-0234